Jerome Boydkirkup

Jerome Boyd-Kirkup currently serves as the Chief Scientific Officer and Co-Founder of Hummingbird Bioscience, where he plays a pivotal role in steering the company's innovative approach to drug discovery and development. At the forefront of integrating artificial intelligence with human biological insights, Jerome oversees the strategic direction of Hummingbird’s cutting-edge technologies, including its proprietary systems biology platforms and computational pipelines. His leadership is instrumental in advancing the company’s pipeline of biotherapeutics targeting hard-to-treat diseases such as cancer and autoimmune disorders.

With a strong background in molecular biology, Jerome brings extensive expertise in systems biology, bioinformatics, and wet lab techniques like genome sequencing and PCR. His scientific acumen enables him to bridge the gap between computational modeling and experimental validation, ensuring that Hummingbird’s drug discovery processes are both innovative and scientifically rigorous. Key projects under his guidance include the development of AI-driven target identification algorithms and the design of novel biologics that leverage deep molecular insights. Jerome’s work emphasizes the importance of integrating genomics, genetics, and virology to understand disease mechanisms at a systems level, facilitating the creation of transformative therapies.

Beyond his technical leadership, Jerome is deeply committed to science communication and fostering collaborative innovation within the biotech industry. His strategic focus on intellectual property management and technology commercialization underscores his role in positioning Hummingbird Bioscience as a leader in the biotherapeutics space. Through his expertise, Jerome continues to push the boundaries of what is possible in precision medicine, striving to deliver impactful treatments for patients with unmet medical needs.